Research.Patient.info

18 driven monogenic autoinflammatory conditions: NLRC4 mutation and XIAP deficiency research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingTherapeutic confirmatory (Phase III)
Open-label extension study with Tadekinig alfa (r-hIL-18BP) to monitor safety and tolerability in patients with IL-18 driven monogenic autoinflammatory conditions: NLRC4 mutation and XIAP deficiency
Germany